• Gilead announces that it is limiting its emergency access program for remdesivir to pregnant women and children under 18 years while it switches to a new program for providing the drug (which been given on a case-by-case basis in China, the European Union (EU), Japan and the United States (US).
• Trump continues to promote chloroquine and hydroxychloroquine during the daily briefing, and by retweeting an opinion piece from the Wall Street Journal advocating for their use in prevention of and treatment for COVID-19. Sources 1,2
